Alzheimer's Clinical Trials Consortium

Are we there yet with PET? – Internal Ethics Committee Webinar Invitation

by

Jason Karlawish, MD, and Joshua Grill, PhD, co-chairs of the Internal Ethics Committee of the Alzheimer’s Clinical Trial Consortium (ACTC, NIA U24 AG057437), together with the committee members invite you to “Are we there yet with PET?” a virtual debate over amyloid PET as a surrogate endpoint for clinically meaningful outcomes. The goal of this debate is to inform the Alzheimer’s field about regulatory approaches that have been applied in the reviews of aducanumab, lecanemab and donanemab. This discussion will be recorded. 4 p.m. February 23, 2023 | Click here to register Topics:
  • “The law and regulation for surrogate endpoints with attention to history and changing interpretations” — Holly Fernandez Lynch, JD, MBe (University of Pennsylvania)
  • “The case for beta-amyloid as measured by PET” — Dennis Selkoe, MD (Harvard University)
  • “The case against beta-amyloid as measured by PET” — Chris van Dyck, MD (Yale University)
Moderated by Jason Karlawish, MD (University of Pennsylvania) Questions? Email tjcasey@upenn.edu

IMPACT-AD is now accepting applications!

by

We are excited to announce that The Institute on Methods and Protocols for Advancement in Clinical Trials in ADRD (IMPACT-AD) is now accepting applications for its 2023 cycle. IMPACT-AD is an exciting opportunity for interested researchers to receive comprehensive training in clinical trials for Alzheimer’s Disease and Related Dementias (ADRD).  Two unique in-person tracks will be offered as part of IMPACT-AD 2023. Tracks will commence simultaneously and overlap. Applicants are permitted to apply to only one track per application cycle.
  • Professionals Track – This track seeks applications from individuals with at least 2 years of experience in AD/ADRD research and/or clinical trials (in a broad variety of roles including, but not limited to clinicians, study coordinators, statisticians, psychometricians, and other study professionals) who wish to further their knowledge and advance their careers in AD/ADRD clinical trials (3.5 days).
  • Fellowship Track – This track seeks applications from individuals seeking to serve as Principal Investigators in AD/ADRD trials now or in the future and offers mentored training in protocol development. Applications are open to individuals in their fellowship or postdoctoral training, faculty members or equivalent positions (5.5 days)
Trainee selection will be competitive; IMPACT-AD will cover all travel costs to attend this meeting. The course will take place at the Estancia Hotel in San Diego, CA, from August 27- September 1, 2023. For more information on the course, please see the attached course Request For Applications. Application instructions and additional information can be found at http://impact-ad.org/. A stated goal of the IMPACT-AD Course is to diversify the nation’s ADRD trialists. As such, we seek applicants from a broad range of geographic, demographic, and professional backgrounds. So, please forward this email to any person or organization that you believe may benefit from this course. We greatly appreciate your help in reaching a broad and diverse audience.

ACTC at Clinical Trials on Alzheimer’s Disease 2022

by

The following itinerary lists some of the sessions and posters where ACTC members are either presenting or have co-authored the presentation. We hope this highlights and provides insight into some of the work being done by ACTC members and collaborators. We look forward to connecting with you all and hope to see you there! ACTC at CTAD2022_HighlightsGuide

ACTC Researchers at CTAD 2021

by

ACTC researchers presented updates at the Clinical Trials on Alzheimer’s Disease conference (CTAD) in Boston, Massachusetts and online. Ron Petersen received a lifetime achievement award and provided the first plenary keynote on a new hope in 2022 for therapeutics in Alzheimer’s. Reisa Sperling presented an update on the AHEAD study with the addition of blood based plasma screening. Jacobo Mintzer presented the design of the LIBBY study, Seth Gale presented the recommendations of handling research information in electronic medical records for preclinical AD research, and Rema Raman spoke on the critical role of biostatistics in Alzheimer’s therapeutic trial design and conduct. Sarah Walter presented recommendations from the ACTC Research Participant Advisory Board around the sharing of genetic and biomarker results in research, and Adam Boxer presented on the current status of tau interventions in AD and the plan for the ACTC Alzheimer’s Tau Platform, currently being reviewed at the NIA.